Daiichi Sankyo Company, Limited

Kobe Gakuin Educational Foundation

Yukiko Sekiguchi

Mitsuhiro Iwamoto

Takeshi Masuda

Makoto Koizumi

Takeshi Honda

Kensuke Nakamura

Kentaro Ito

Takahide Nishi

Yoshiyuki Onishi

Tsuyoshi Nakamura

Masafumi Matsuo

Futoshi Nara

Takaichi Shimozato

Shinnosuke Tsuji

Yoshirou Kawaguchi

Hiroyuki Chaya

Yumiko Mizuno

Shohei Oishi

Ryuki Miyauchi

The present invention establishes a molecular therapy for glycogen storage disease type Ia. The present invention provides an oligonucleotide of 15-30 bases comprising a nucleotide sequence complementary to die cDNA of G6PC gene with c.648G>T mutation, wherein the oligonucleotide comprises a sequence complementary to a region comprising any site between the 82to the 92nucleotide from the 5′ end of exon 5 of the G6PC gene with c.648C>T mutation, a pharmacologically acceptable salt or solvate thereof. Also provided is a pharmaceutical drug comprising the oligonucleotide, a pharmacologically acceptable salt or solvate thereof (e.g., therapeutic drug for glycogen storage disease type Ia).

Therapeutic agent for glycogen storage disease type IA

The present invention provides a conjugate comprising a hANP peptide bonded via a polyethylene glycol linker to a glycan attached to Asn297 of a Fc-containing molecule (N297 glycan), or a pharmaceutically acceptable salt thereof, a medicament comprising the same as an active ingredient, a method for producing the same, etc.

HANP-Fc-containing molecular conjugate

The present invention provides an EndoS mutant enzyme having an amino acid sequence of EndoS D233Q and further having a particular additional mutation and exhibiting a reduced hydrolysis activity, in comparison with the activity of EndoS D233Q, to an N-linked sugar chain (N297-linked sugar chain) linked to Asn at position 297 in IgG and a gene encoding the same.

Endos mutant enzyme

A compound having immunosuppressive activity with low toxicity or a pharmacological salt thereof. The compound has a general formula (I) shown below or a pharmacologically acceptable salt thereof, or a pharmacologically acceptable prodrug thereof 

Heterocyclic compound

Growing community of inventors

Tokyo, Japan

Yukiko Sekiguchi